Long-term treatment with NTQ5082 for people who already benefited
Treatments studied
Part of Blood & lymphatic clinical trials.
This study continues to give the drug NTQ5082 to people who already took part in an earlier trial and saw benefits. It aims to see how well the drug works over a longer period and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have already completed an earlier NTQ5082 study, or you must have been in the control group getting eculizumab.
- The earlier treatment must have helped you, and you must be likely to benefit from continuing it.
- You must have had the meningococcal and pneumococcal vaccines as required earlier, and their protection should still be active during this study.
- You must agree to use effective birth control during the study and for 4 weeks after the last dose, and not donate sperm or eggs.
- You cannot have had a bone marrow or organ transplant, your spleen removed, a history of certain serious infections (like tuberculosis), or a cancer in the last 5 years (except some cured skin or thyroid cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental pill called NTQ5082 for people with PNH who haven't been treated with complement inhibitors before. The goal is to see if it can improve anemia and control PNH symptoms like fatigue and blood clots.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This study tests a new pill (FXS6837) against a standard treatment (eculizumab) for people with PNH. The goal is to see if the pill is safe and effective in improving anemia and reducing the need for transfusions.
This trial tests an investigational drug called NM8074 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been treated with complement inhibitors. The goal is to see if NM8074 can reduce red blood cell destruction and improve anemia, potentially reducing the need for blood transfusions.
This study is a follow-up for people who already finished the earlier phase 2 trial of the study drug LP-005 for PNH. The goal is to see if it's safe and effective for long-term treatment.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.